Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age \> 18 years.~2. Patients diagnosed with localized scleroderma diseases during inactive stage with fibrotic and atrophic cutaneous lesions confirmed histologically.~3. Understanding the nature of the study and Signature of the written informed consent.~4. Negative pregnancy test at study entry for females of child bearing potential.~5. If the patient is a female of childbearing potential (less than 24 months since the last menstrual bleeding), she is using an acceptable and effective method of contraception during the study period.~Exclusion Criteria:~1. Patients under treatment with steroid therapy and/or systemic immunosuppressive therapy within 1 month prior to screening.~2. Patients with ongoing infectious processes at the level of target lesions.~3. Women who are pregnant or breast feeding.~4. Know allergy or hypersensitivity to the active principle of the investigational drug or to one of its excipients.~5. Patients with a condition or concurrent severe and/or uncontrolled medical disease which could compromise his/her participation, compliance with and/or completion of study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polydeoxyribonucleotides (Type: EXPERIMENTAL): PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).